News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-european-medicines-agency-acceptance

https://seekingalpha.com/article/4750265-immunitybio-making-its-next-strikes-after-bladder-cancer-approval

https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-provides-regulatory-update-anticipated-fda?field_nir_news_date_value[min]=

https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-provides-regulatory-update-global-submission-anktiva?field_nir_news_date_value[min]=

PD-L1 Targeted High-Affinity Natural Killer Cell and IL-15 Superagonist N-803-Based Therapy Extends Overall Survival of Advanced Metastatic Pancreatic Cancer Patients  (Provisionally accepted) https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1472714/abstract

ImmunityBio follows through in lung cancer https://www.oncologypipeline.com/apexonco/node/1044

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-permanent-j-code-j9028-anktivar-now?field_nir_news_date_value[min]=

https://seekingalpha.com/article/4744437-immunitybio-forging-a-new-plan-after-recent-100-million-offering

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-inc-announces-pricing-public-offering-common-stock?field_nir_news_date_value[min]=

https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-inc-announces-proposed-public-offering-common-stock

https://www.observertoday.com/news/top-stories/2024/11/town-hopeful-after-immunitybio-tour/